Literature DB >> 26117623

Serial Optical Coherence Tomography Evaluation at 6, 12, and 24 Months After Biolimus A9-Eluting Biodegradable Polymer-Coated Stent Implantation.

Akihide Konishi1, Toshiro Shinke2, Hiromasa Otake1, Tomofumi Takaya1, Tsuyoshi Osue1, Hiroto Kinutani1, Masaru Kuroda1, Hachidai Takahashi1, Daisuke Terashita1, Junya Shite1, Ken-ichi Hirata1.   

Abstract

BACKGROUND: The Nobori (Terumo Corporation, Tokyo, Japan) is a biolimus A9-eluting stent (BES) featured with a biodegradable polymer coated on the abluminal side only. We previously reported that favourable vessel healing was achieved at 6-12 months after BES implantation. However, detailed long-term vessel reaction after BES deployment is unclear.
METHODS: Twenty-two BESs were serially evaluated using optical coherence tomography (OCT) at 6, 12, and 24 months after stenting. Average neointimal thickness, uncovered struts, and neointimal unevenness score (each cross-section as maximum neointimal thickness in 1 cross section divided by the average neointimal thickness of the same cross-section) were manually measured. In addition, we evaluated the percentage of struts with peri-strut low-intensity area (a region around stent struts that homogenously showed less intensity than the surrounding tissue, which suggests fibrin deposition or impaired neointima maturation), thrombi, and atherogenic neointimas (neointimas containing a diffuse border and poor-signal region with invisible struts due to marked signal attenuation).
RESULTS: Serial OCT observation revealed a small gradual increase in neointimal thickness from 6 to 24 months (73 ± 24 μm; 81 ± 26 μm; and 108 ± 35 μm, respectively, P = 0.001) with a nonsignificant decrease in the lumen area (6.36 ± 1.98 mm(2); 6.18 ± 2.04 mm(2); and 5.87 ± 2.06 mm(2); P = 0.72). Frequency of uncovered struts (3.89 ± 3.91%; 1.55 ± 1.63%; and 0.23 ± 0.67%; P = 0.001), neointimal unevenness score (1.95 ± 0.18% to 1.86 ± 0.19% to 1.78 ± 0.17; P = 0.012), percentage of thrombi (5%, 0%, and 0%; P = 0.37) and peri-strut low-intensity area (6.8%, 5.1%, and 1.6%; P = 0.017) decreased from 6 to 12 and 24 months. Atherogenic neointima was not observed in the event-free OCT cohort.
CONCLUSIONS: The Nobori stent achieved acceptable long-term vessel healing, mostly without adverse vessel reactions.
Copyright © 2015 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26117623     DOI: 10.1016/j.cjca.2015.02.036

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  3 in total

Review 1.  Intracoronary Imaging in the Detection of Vulnerable Plaques.

Authors:  Jonathan A Batty; Shristy Subba; Peter Luke; Li Wing Chi Gigi; Hannah Sinclair; Vijay Kunadian
Journal:  Curr Cardiol Rep       Date:  2016-03       Impact factor: 2.931

2.  Third generation drug eluting stent (DES) with biodegradable polymer in diabetic patients: 5 years follow-up.

Authors:  Marcus Wiemer; Sinisa Stoikovic; Alexander Samol; Zisis Dimitriadis; Juan M Ruiz-Nodar; Ralf Birkemeyer; Jacques Monsegu; Gérard Finet; David Hildick-Smith; Damras Tresukosol; Enrique Garcia Novo; Jacques J Koolen; Emanuele Barbato; Gian Battista Danzi
Journal:  Cardiovasc Diabetol       Date:  2017-02-10       Impact factor: 9.951

3.  Vascular response to biolimus A-9 eluting stent in patients with shorter and prolonged dual antiplatelet therapy: optical coherence tomography sub-study of the NIPPON trial.

Authors:  Koji Kuroda; Toshiro Shinke; Hiromasa Otake; Hiroto Kinutani; Raisuke Iijima; Junya Ako; Hisayuki Okada; Yoshiaki Ito; Kenji Ando; Hitoshi Anzai; Hiroyuki Tanaka; Yasunori Ueda; Shin Takiuchi; Yasunori Nishida; Hiroshi Ohira; Katsuhiro Kawaguchi; Makoto Kadotani; Hiroyuki Niinuma; Kazuto Omiya; Takashi Morita; Kan Zen; Yoshinori Yasaka; Kenji Inoue; Sugao Ishiwata; Masahiko Ochiai; Toshimitsu Hamasaki; Kazushi Urasawa; Toru Kataoka; Minoru Yoshiyama; Kenshi Fujii; Takumi Inoue; Masahito Kawata; Hiroyoshi Yokoi; Masato Nakamura
Journal:  Heart Vessels       Date:  2018-02-20       Impact factor: 2.037

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.